Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-18 · Built: 2026-10-18 · 中文

← United States · Coverage record

US · SEC FORM 4

Quoin Pharmaceuticals, Ltd.

QNRX · Nasdaq · CIK 0001671502 · Healthcare · Biotechnology

INSIDER SIGNAL

67.4 / 100

4 buyers · 4 purchase transaction lines · $280.0K gross purchase

WHY THIS SIGNAL?

Buyer breadthStrong
Purchase sizeModerate
RoleModerate
RecencyLow
ConvictionStrong
Score anatomy

Each bar shows the contribution to the current score; the weights and formula stay unchanged.

Cluster+28.0 / 35
Purchase size+11.9 / 25
Role+13.0 / 20
Recency+4.5 / 10
Conviction+10.0 / 10

What is holding the score back?

  • ⚠ Purchase size is modest relative to the model scale
  • ⚠ Role scores low · most senior buyer: Chief Executive Officer (CEO, chair and 10% owners score lowest)
  • ✓ Cluster breadth is broad · 4+ insiders

Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.

US-v1.2 ranks qualifying equity purchases under the current 180-day rules. The score is a research priority, not a return forecast or probability. Backtests have not shown that a higher US score is followed by better returns.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
Culverwell Anthony JamesDirector
○●
Carter Denise P.Chief Operating Officer
●
Myers MichaelChief Executive Officer
●
Lawlor Sally BridgetChief Financial Officer
●
LANGER DENNISDirector
○
● Purchase▼ Sale○ Other

—

Purchase breadth & concentration

QUALIFYING BUYERS4
PURCHASE CONCENTRATION36%Largest buyer: Carter Denise P. · $100.0K
CLUSTER BUYING · 15D4 insidersPeak activity: 2026-08-31–2026-08-31

Roles in the peak window: Chief Executive Officer, Chief Financial Officer, Chief Operating Officer, Director. Concentration uses priced qualifying P lines only and does not change the saved score.

SIGNAL HISTORY

67.4 / 100

Latest recorded score

↓ -0.2 ptsversus the previous recorded snapshot
  1. 67.9
  2. 67.8
  3. 67.7
  4. 67.6
  5. 67.4

Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.

Recent Form 4 activity

4Purchases
0Sales
2Other Form 4 lines
6SEC filings · 365 days
BUYING4 qualifying P line(s) · 180 days
SELLING0 sale line(s) · context only
OTHER2 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context provides additional background on recent price performance and risk. It does not affect the Insider Signal.

Price performance

1M
-34.8%
3M
+6.4%
6M
-23.7%
12M
-45.1%

Volatility & liquidity

Volatility
164.7%
Beta
—
Avg daily value
USD 2.5M

Valuation

Market cap
USD 316.3M
P/E
—

Fundamentals

Profit margin
—
ROE
-120.4%
Industry
Biotechnology

Market data

Price data up to: 2026-10-11 · Price source: OpenBB/yfinance; volume from price cache (yfinance) · From SEC filings: Market cap, ROE · Fiscal year ended: 2025-12-31 · Market cap is the shares outstanding stated on the filing cover multiplied by the latest close. Share count date: 2026-08-12 · Status: PASS

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
65,473
Previous report
126,292
Avg daily volume
47,416
Days to cover
1.4

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2026-08-31Myers MichaelPurchase (P)ADSs20,490USD 4.88USD 99,991SEC filing ↗
2026-08-31Lawlor Sally BridgetPurchase (P)ADSs10,244USD 4.88USD 49,991SEC filing ↗
2026-08-31Culverwell Anthony JamesPurchase (P)ADSs6,146USD 4.88USD 29,992SEC filing ↗
2026-08-31Carter Denise P.Purchase (P)ADSs20,490USD 4.88USD 99,991SEC filing ↗
2025-10-14LANGER DENNISPurchase (P)ADSs15,152USD 8.49USD 128,640SEC filing ↗
2024-12-23Myers MichaelPurchase (P)Ordinary Shares555,556USD 0.45USD 250,000SEC filing ↗
2024-12-23Dunn GordonPurchase (P)Ordinary Shares122,221USD 0.45USD 54,999SEC filing ↗
2024-12-23Culverwell Anthony JamesPurchase (P)Ordinary Shares100,000USD 0.45USD 45,000SEC filing ↗
2024-12-23Carter Denise P.Purchase (P)Ordinary Shares555,556USD 0.45USD 250,000SEC filing ↗
2024-09-10Dunn GordonPurchase (P)Ordinary Shares20,000USD 0.81USD 16,200SEC filing ↗
2024-09-09Dunn GordonPurchase (P)Ordinary Shares8,856USD 0.79USD 7,005SEC filing ↗
2024-09-04Myers MichaelPurchase (P)Ordinary Shares37,094USD 0.77USD 28,520SEC filing ↗
2024-09-04Carter Denise P.Purchase (P)Ordinary Shares31,813USD 0.79USD 25,009SEC filing ↗
2024-09-03Myers MichaelPurchase (P)Ordinary Shares800USD 0.62USD 496SEC filing ↗
2024-09-03Carter Denise P.Purchase (P)Ordinary Shares5,922USD 0.65USD 3,854SEC filing ↗

Form 4 evidence

6 transaction lines in the latest 365-day window; 25 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-08-31Myers MichaelPurchase (P)ADSs20,490USD 4.88USD 99,991SEC filing ↗
2026-08-31Lawlor Sally BridgetPurchase (P)ADSs10,244USD 4.88USD 49,991SEC filing ↗
2026-08-31Culverwell Anthony JamesPurchase (P)ADSs6,146USD 4.88USD 29,992SEC filing ↗
Show recent Form 4 evidence (6 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-08-31Myers MichaelPurchase (P)ADSs20,490USD 4.88USD 99,991SEC filing ↗
2026-08-31Lawlor Sally BridgetPurchase (P)ADSs10,244USD 4.88USD 49,991SEC filing ↗
2026-08-31Culverwell Anthony JamesPurchase (P)ADSs6,146USD 4.88USD 29,992SEC filing ↗
2026-08-31Carter Denise P.Purchase (P)ADSs20,490USD 4.88USD 99,991SEC filing ↗
2026-08-27LANGER DENNISAward / grant (A)ADSs34,534USD 5.15USD 177,850SEC filing ↗
2026-08-27Culverwell Anthony JamesAward / grant (A)ADSs31,352USD 5.15USD 161,463SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-18
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerQNRX
CIK0001671502
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2834 Pharmaceutical Preparations
ExchangeNasdaq

Data coverage

Local Form 4 history25 transaction lines from 2024-06-07 to 2026-08-31
22 P purchase lines · 1 S sale lines · 2 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.